transplantation in hiv
DESCRIPTION
Transplantation in HIV. Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH. Background. HIV-infected patients have been excluded from consideration for transplantation because: 1. Morbidity too high to justify organ use - PowerPoint PPT PresentationTRANSCRIPT
Transplantation in HIV
Michelle Roland, MD
Assistant Professor of Medicine
UCSF Positive Health Program at SFGH
Background
• HIV-infected patients have been excluded from consideration for transplantation because:1. Morbidity too high to justify organ use2. Immunosuppression might accelerate HIV disease
• Mortality is reduced with HAART
• Prospective study will evaluate:1. Effect of immunosuppression on survival and HIV disease
2. Effect of HIV on graft survival
3. Drug interactions between PI/NNRTI and immunosuppressives
• Many centers transplanted patients prior to the study
Methods
• Prospective analysis of enrolled subjects +• Retrospective review of recipients at study centers
• “Eligible” subjects: • No opportunistic infection history• CD4 > 200 kidney; >100 liver• HIV RNA < 50 kidney, liver or unable to tolerate ARVs in liver
but post-transplant suppression predicted
• “Ineligible” subjects:• Did not meet 1 or more criteria above
Results: Baseline• 41 “Eligible” Subjects
• 22 Kidney and 19 Liver
• 8 “Ineligible” Subjects• undiagnosed HIV, HIV RNA > 50 (K), low
CD4, altered MS, history of OI/ON
• Baseline CD4+ T Cell CountsKidney: 455 (200 - 1054)Liver: 321 (103 - 973)
• Baseline HIV-1 RNALiver: <50 (<50 - 115,776)
Results: Outcomes
• Median follow-up 279 days (3 - 1567)
• Deaths 1 kidney + 3 liver
- recurrent hepatitis C
- rejection after PI stopped
- post-op complications x 2
• Opportunistic Complications
1 liver + 1 kidney
- CMV esophagitis
- candida esophagitis
Results: Outcomes
• CD4+ T Cell CountsKidney 460 (76 - 1300)Liver 296 (89 - 590)
• HIV-1 RNAKidney < 50 (< 50 - 11,343)
Liver <50 (<50 - 80)
• Re-transplantation 1 liver• Graft loss 1 kidney• Additional rejection 36% kidney + 11% liver
Outcomes: Ineligible Subjects
• Undiagnosed HIV death (MAC< PML)
• Altered MS death (PML)
• HIV RNA > 50 (K) all <50 or < 400
• Low CD4 stable 76 --> 102
• History of OI/ON
(PCP + CMV; KS + CMV) no recurrence at
15 months and 5
weeks
Conclusions
• Patient survival is comparable to UNOS data at 1 year95% kidney subjects UNOS = 94.8% cadaver/97.6% living
84% liver subjects UNOS = 87.9%
• No significant HIV disease progression in selected pts• 2 OI s could be due to HIV or immunosuppression• Stable CD4+ T-cell counts and suppressed HIV-1 RNA
• There is HIV progression with advanced disease
• Graft survival is comparable to UNOS data at 1 year89% kidney subjects UNOS = 89.4% cadaver/94.5% living
84% liver subjects UNOS = 81.4%